Neuroprotection in Neurodegeneration

Name: Neuroprotection in Neurodegeneration
Availability: OutOfStock
ISBN: 9780387825427

ISBN-10: 0387825428

ISBN-13: 9780387825427

Edition: N/A

Authors: M. B. Youdim, P. Reiderer, J. Fritze

List price: $73.00

30 day, 100% satisfaction guarantee!

Out of stock

We're sorry. This item is currently unavailable.

what's this?

Rush Rewards U
Members Receive:

You have reached 400 XP and carrot coins. That is the daily max!

Book details

List price: $73.00
Publisher: Springer
Binding: Hardcover
Size: 8.25" wide x 10.50" long x 0.50" tall
Weight: 1.430
Language: English



The calcium ion and cell death



Clinical experiences with nimodipine in cerebral ischemia



Adenosine - an endogenous neuroprotective metabolite and neuromodulator



Neuroprotective effects of TGF-[beta]1



New mechanisms of excitatory transmitter neurotoxicity



The glycine binding site of the NMDA receptor: involvement in neurodegeneration and new approach for neuroprotection



Interactions of neurotoxins with non-NMDA glutamate receptors: an autoradiographic study



Behavioural effects of NMDA-receptor antagonists



Glutamate receptor antagonists in cerebral ischaemia



The competitive NMDA receptor antagonist CGP 40116 is a potent neuroprotectant in a rat model of focal cerebral ischemia



Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties



Nitric oxide synthase in the brain: light and electron microscopical findings based on the NADPH-diaphorase reaction



The enigma of neuromelanin in Parkinson's disease substantia nigra



Blood to brain iron uptake in one Rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol



MPTP-induced degeneration: interference with glutamatergic toxicity



Influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, lipoic acid and L-deprenyl on the interplay between cellular redox systems



Clinical aspects of neuroprotection in Parkinson's disease



Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment



Neuroprotection by dopamine agonists



Hypothalamic dysfunction in dementia



Therapy of Alzheimer disease: symptomatic or neuroprotective?



Pharmacological evaluation of phenylcarbamates as CNS-selective acetylcholinesterase inhibitors



Subject Index